# Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)

> **NCT01530048** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 34 (actual)

## Conditions studied

- Diabetes
- Healthy

## Interventions

- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT01530048
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01530048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01530048, "Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01530048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*